Traded Jan 6 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Dec 19, 2025 · Filed Dec 23, 2025
A Arrowhead Pharmaceuticals director sold $206K of Arrowhead Pharmaceuticals shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$206,103
Shares × reported transaction price
24 days after results of Nov 25, 2025, 48 days before results of Feb 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −5.3% | −1.2% | −4.1% |
| 30 days | −4.4% | −0.2% | −4.2% |
| 90 days | −19.7% | −5.4% | −14.3% |
| 180 days | +17.0% | +7.8% | +9.1% |
Past results only. Not a forecast.
Traded Jan 6 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Jan 6 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Jan 6 · filed 2 days later
Gift or transfer — classified separately from trades.